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Members of the 18 glycosyl hydrolase (GH 18) gene
family have been conserved over species and time
and are dysregulated in inflammatory, infectious,
remodeling, and neoplastic disorders. This is partic-
ularly striking for the prototypic chitinase-like pro-
tein chitinase 3-like 1 (Chi3l1), which plays a critical
role in antipathogen responses where it augments
bacterial killing while stimulating disease tolerance
by controlling cell death, inflammation, and remod-
eling. However, receptors that mediate the effects
of GH 18 moieties have not been defined. Here,
we demonstrate that Chi3l1 binds to interleukin-13
receptor a2 (IL-13Ra2) and that Chi3l1, IL-13Ra2,
and IL-13 are in a multimeric complex. We also
demonstrate that Chi3l1 activates macrophage
mitogen-activated protein kinase, protein kinase
B/AKT, and Wnt/b-catenin signaling and regulates
oxidant injury, apoptosis, pyroptosis, inflamma-
some activation, antibacterial responses, melanoma
metastasis, and TGF-b1 production via IL-13Ra2-
dependent mechanisms. Thus, IL-13Ra2 is a GH
18 receptor that plays a critical role in Chi3l1
effector responses.INTRODUCTION
The 18 glycosyl hydrolase (GH 18) gene family contains true
chitinases (Cs) that degrade chitin polysaccharides and chiti-
nase-like proteins (CLPs) that bind to but do not degrade chitin
(Lee et al., 2011). They are members of an ancient gene family
that exists in species as diverse as plants and humans and830 Cell Reports 4, 830–841, August 29, 2013 ª2013 The Authorshas evolved during speciation, with a particularly impressive
increase in CLPs coinciding with the appearance of mammals
(Aerts et al., 2008; Funkhouser and Aronson, 2007). This reten-
tion over species and evolutionary time has led to the belief
that these moieties play essential roles in biology. Recent
studies have confirmed this speculation (Dela Cruz et al.,
2012; Lee et al., 2009, 2011; Lee and Elias, 2010; Sohn
et al., 2010). This is particularly true for the prototypic CLP chi-
tinase 3-like-1 (Chi3l1, also called YKL-40 in humans and BRP-
39 in mice), which has been shown by our laboratory and
others to play major roles in antipathogen, antigen-induced,
oxidant-induced, inflammation, repair and remodeling re-
sponses by regulating a variety of essential biologic processes
including oxidant injury apoptosis, pyroptosis, inflammasome
activation, Th1/Th2 inflammatory balance, M2 macrophage dif-
ferentiation, transforming growth factor b1 (TGF-b1) elabora-
tion, dendritic cell accumulation and activation, and mitogen-
activated protein kinase (MAPK) and Akt signaling (Areshkov
et al., 2012; Chen et al., 2011a; Dela Cruz et al., 2012; Kim
et al., 2012; Lee et al., 2009; Sohn et al., 2010). The potential
importance of YKL-40/Chi3l1/BRP-39-induced responses can
also be seen in the large number of diseases in which
Chi3l1/YKL-40 excess has been documented and the observa-
tion that the degree of Chi3l1/YKL-40 dysregulation often cor-
relates with the severity and natural history of these disorders
(reviewed in Coffman, 2008; Lee et al., 2011). Surprisingly, the
mechanisms via which the GH 18 moieties mediate their bio-
logic effects are poorly understood. Importantly the possibility
that GH 18 proteins mediate their biologic effects via a ligand-
receptor paradigm has not been addressed, and moieties that
bind to and signal in response to any of these regulators have
not been defined.
To address the possibility that YKL-40/Chi3l1/BRP-39, which
does not have known enzymatic activity, mediates its effects
via identifiable receptors, we used yeast two-hybrid binding
and colocalization assays to define YKL-40/Chi3l1/BRP-39
binding-partner interactions and assessments of signaling, gene
expression, and in vivo phenotype generation to evaluate the
consequences of these interactions. These studies demonstrate
that YKL-40/Chi3l1/BRP-39 binds to interleukin-13 receptor a2
(IL-13Ra2). They also demonstrate that YKL-40/Chi3l1/BRP-39,
IL-13Ra2, and IL-13 are in a multimeric complex. Lastly, they
demonstrate that YKL-40 activates MAPK, Akt, and Wnt/b-cate-
nin signaling pathways and regulates apoptosis, pyroptosis, in-
flammasome activation, oxidant injury, antibacterial responses,
melanoma metastasis, and TGF-b1 elaboration via IL-13Ra2-
dependent mechanisms.
RESULTS
Chi3l1/YKL-40/BRP-39 Binding to IL-13Ra2
To define the binding partners of Chi3l1/YKL-40, yeast two-
hybrid analysis was undertaken using Chi3l1/YKL-40 as bait.
A number of clones gave positive results in these assays. One
of the most intriguing encoded IL-13Ra2 (Figure S1A). Further
documentation of the interaction between YKL-40 and IL-
13Ra2 was obtained with coimmunoprecipitation (coIP), coloc-
alization, and Biacore assays. In the former, A549 cells were
transfected with both of these moieties and subjected to immu-
noprecipitation (IP) with antibodies to one moiety, and the
precipitate was then analyzed via western blotting using anti-
bodies to the other moiety. In these experiments, the two moi-
eties always traveled together with IP using antibodies against
YKL-40 always precipitating IL-13Ra2 and vice versa (Figure 1A).
Immunohistochemical evaluations of lungs from IL-13 transgenic
(Tg) mice (in which Chi3l1/BRP-39 and IL-13Ra2 are both
strongly induced) demonstrated that Chi3l1/BRP-39 and
IL-13Ra2 frequently colocalize in these tissues (Figure 1B). The
major site of this colocalization was in F4/80+ macrophages
(Figures 1B and S1B). Interestingly, there were macrophage
populations in which colocalization occurred and populations
in which Chi3l1 was noted and IL-13Ra2 could not be detected
(Figure 1B). Colocalization in some alveolar type II cells was
also appreciated (Figures 1B and S1C). To identify the sites in
the cell of this colocalization, we employed fluorescence-acti-
vated cell sorting (FACS) evaluations of nonpermeabilized cells
and immunohistochemistry (IHC) of tissue sections and stained
both with anti-Chi3l1 and anti-iL-13Ra2. These studies clearly
demonstrate that Chi3l1 and IL-13Ra2 can be seen together
on the surface and in the cytoplasm of the cell (Figures 1C and
S1D). The Biacore assays also demonstrated that Chi3l1/YKL-
40 and IL-13Ra2 bind to one another. At pH 7.4, the binding
was quite avid, with a Kd of 23 ± 14 pM (Figure 1D). The koff
was approximately 105 s1 and the kon was 3.39 ± 1.54 3
105M1 s1. These studies demonstrate that YKL-40 specifically
binds to IL-13Ra2 with high affinity.
Localization of Chi3l1/YKL-40-IL-13Ra2 Binding
Deletion mapping was next employed to define the regions in
Chi3l1/YKL-40 and IL-13Ra2 that are required for their interac-
tions in the yeast two-hybrid assay. These studies demonstrated
that the region of YKL-40 between amino acids 22 and 357
contained the elements that were required to bind to full-length
IL-13Ra2 (Figure 1E). This region is called the catalytic domain(CD) of GH 18 moieties and contains the chitin binding
motif (CBM) but does not contain its signal peptide (SP) or the
C-terminal peptide (Figure 1E). Interestingly, the CBM was
necessary, but not sufficient, for YKL-30/Chi3l1-IL-13Ra2 bind-
ing (Figure 1E). These studies also demonstrated that the
extracellular domain (ECD) of YKL-40 contained elements that
were required for binding to full-lengthChi3l1/YKL-40 (Figure 1E).
The transmembrane and intracellular motifs of IL-13Ra2 did not
play a critical role in this interaction (Figure 1F). The four sites
of N-linked glycosylation within the ECD were also able to be
mutated without abrogating IL-13Ra2 ECD-Chi3l1/YKL-40 bind-
ing (Figure 1F). These studies demonstrate that Chi3l1/YKL-40/
IL-13Ra2 binding is dependent on the CD and the CBM of the
former and the ECD, but not the sites of N-glycosylation in the
latter.
Interactions with Soluble IL-13Ra2
An ECD-containing soluble version of this receptor has been
described elsewhere (Chen et al., 2008, 2009). We thus specu-
lated that Chi3l1/YKL-40 would also bind to soluble IL-13Ra2
(sIL-13Ra2). To test this hypothesis, we did coIP experiments
using bronchoalveolar lavage (BAL) fluids from IL-13 Tg mice.
These studies demonstrated that Chi3l1/BRP-39 also binds to
sIL-13Ra2 (Figure S1E).
Role of IL-13Ra2 in Chi3l1/YKL-40/BRP-39 Signaling
To define the role(s) of IL-13Ra2 in Chi3l1/YKL-40/BRP-39-
induced intracellular signaling, we compared the effects of
Chi3l1/YKL-40/BRP-39 on MAPK, extracellular signal-regulated
protein kinase (ERK) 1/2, AKT, and Wnt/b-catenin activation
in human THP-1 cells treated with IL-13Ra2 small interfering
RNA (siRNA) or scrambled controls and peritoneal macro-
phages from wild-type (WT) and IL-13Ra2 null mice. As can
be seen in Figure 2A, ERK activation, AKT activation, and the
induction of nuclear b-catenin and c-fos were seen in THP-1
cells 30 min to 2 hr after the addition of recombinant (r)
Chi3l1/YKL-40. These effects were dose dependent, with the
activation of ERK and AKT being seen with doses of rYKL-40
as low as 0.1–0.3 mg/ml and the induction of nuclear b-catenin
and c-fos being seen with doses as low as 0.3–0.5 mg/ml (Fig-
ure 2B). They were also at least partially IL-13Ra2 dependent,
because siRNA that decreased the levels of IL-13Ra2
messenger RNA (mRNA) by greater than 70% (Figures S2A
and S2B) significantly decreased each of these activation
events (Figure 2C). In accord with these findings, rChi3l1/
BRP-39 activated ERK and AKT signaling and induced nuclear
b-catenin and c-fos accumulation in peritoneal macrophages
from WT mice, and these inductive events were significantly
decreased in cells from IL-13Ra2 null animals (Figure 2D).
These effects were at least partially Chi3l1/YKL-40/BRP-39
specific because the related GH 18 moiety, acidic mammalian
chitinase (AMCase), did not signal in a similar manner via IL-
13Ra2 (Figure S2C). Interestingly, Chi3l1/YKL-40/BRP-39
signaling was also significantly decreased in experiments in
which soluble IL-13Ra2 was added to the cell culture system
(Figures 2E and S2D). These studies demonstrate that Chi3l1/
YKL-40/BRP-39 activates ERK and AKT signaling and
induces b-catenin nuclear translocation and c-fosCell Reports 4, 830–841, August 29, 2013 ª2013 The Authors 831
Figure 1. Binding and Localization of Chi3l1/YKL-40 and IL-13Ra2
(A) A549 cells were transfected with Chi3l1/YKL-40 (Chi3l1) and/or human IL-13Ra2 (IL-13Ra2), lysates were prepared and immunoprecipitated (IP) with either
anti-Chi3l1 or anti-iL-13Ra2, and the precipitates were evaluated using immunoblot (IB) analysis as noted.
(B) Triple-label IHC to detect the colocalization of IL-13Ra2 and BRP-39 in the macrophages (upper panels) and type 2 alveolar epithelial cells (lower panels) in
lungs from IL-13 Tg mice using antibodies to BRP-39, IL-13Ra2, and cell-specific markers of macrophages (anti-F4/80) and type 2 epithelial cells (anti-SP-C).
Arrows highlight some of the colocalized cells.
(C) Cell surface colocalization of Chi3l1/YKL-40 (Chi3l1) and IL-13Ra2 (IL-13Ra2). THP-1 cells were incubated in the presence or absence of anti-YKL-40-biotin
antibody and anti-iL-13Ra2 immunoglobulin G (IgG) antibody without permeabilization. They were then washed and stained with streptavidin (SA)-PE and
anti-igG-APC and subjected to flow cytometric analysis.
(D) Measurement of the affinity and kinetics of IL-13Ra2 binding to Chi3l1/YKL-40 by surface plasmon resonance (SPR). Chil3l1/YKL-40 was immobilized and
IL-13Ra2 was in the mobile phase.
(legend continued on next page)
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Figure 2. Chi3l1 and IL-13Ra2 Regulation
of Macrophage Signaling
(A and B) THP-1 cells were incubated with re-
combinant Chi3l1/YKL-40 (rChi3l1) for the noted
periods of time at the noted doses. Western
blot evaluations were used to evaluate ERK1/2
phosphorylation (ERK-P), total ERK 1/2 (ERK-T),
AKT phosphorylation (AKT-P), total AKT (AKT-T),
b-catenin nuclear translocation, and nuclear c-fos
accumulation.
(C and D) The role(s) of IL-13Ra2 in these
responses was assessed by comparing these
signaling events in THP-1 cells treated with IL-
13Ra2 siRNA (siRNA+) or scrambled controls
(siRNA) (C) and peritoneal macrophages from
wild-type (+/+) and IL-13Ra2 null (/) mice (D).
Each panel is representative of a minimum of
three evaluations.
(E) The effects of recombinant soluble IL-13Ra2
(rsIL-13Ra2) on Chi3l1-stimulated signaling were
also assessed. In these experiments, peritoneal
macrophages from WT and IL-13Ra2 null mice
were treated with PBS or rsIL-13Ra2 and rChi3l1
as indicated and ERK and AKT activation was
evaluated by western blot analysis.
(F) Peritoneal macrophages from IL-13Ra2 null
(/) mice was transfected with full-length (FL)
IL-13Ra2, a truncated construct (TC) of IL-13Ra2
that lacked its intracellular domain, or an empty
vector. After incubation of the cells with rChi3l1
(500 ng/ml) as indicated, cell lysates were pre-
pared and ERK and AKT activation was evaluated
by western blot analysis. See also Figure S2.accumulation via an IL-13Ra2-dependent mechanism(s) in
mice and humans and that this signaling is regulated by sIL-
13Ra2.
Given that the intracellular domain of IL-13Ra2 only contains
a 17-amino-acid structure that lacks protein binding motifs,
studies were undertaken to define the role of this domain
in Chi3l1/YKL-30/BRP-39 signaling events. To address this
question, we compared the signaling induced by Chi3l1/YKL-
40/BRP-39 in macrophages from IL-13Ra2 null mice that
were transfected with WT (full-length) IL-13Ra2 constructs or(E) Yeast two-hybrid characterization of the structures in hChi31 that bind to IL-13Ra2. The 18GHcatalytic dom
(SP), and C-terminal fragment are illustrated.
(F) Yeast two-hybrid characterization of the structures in IL-13Ra2 that bind to hChi31. The extracellular doma
domain (ICD), signal peptide (SP), and sites of N-glycosylation (N) are illustrated.
Each panel is representative of a minimum of three evaluations. Scale bars in (B) represent 10 mm. See also
Cell Reports 4, 830–841truncated constructs that lacked
the intracellular domain. These studies
demonstrate that the intracellular do-
main of IL-13Ra2 is not required for
Chi3l1 activation of MAPK or AKT (Fig-
ure 2F). Interestingly, this segment was
required for Chi3l1 activation of the
Wnt/b-catenin pathway (Figure S2E).
These studies demonstrate that the
intracellular domain of IL-13Ra2 hasdifferent roles in Chi3l1-induced MAPK and AKT versus Wnt/
b-catenin signaling.
Interactions of IL-13, IL-13Ra2, and
Chi3l1/YKL-40/BRP-39
Because IL-13 also binds to IL-13Ra2, we used coIP, signaling,
and Biacore experiments to define the interactions of IL-13,
Chi3l1/YKL-40/BRP-39, and IL-13Ra2. These studies demon-
strated that IL-13 and Chi3l1/YKL-40/BRP-39 do not bind to
one another (data not shown). They did, however, demonstrateain (CD), chitin bindingmotif (CBM), signal peptide
in (ECD), transmembrane domain (TD), intracellular
Figure S1.
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Figure 3. Interactions of IL-13, IL-13Ra2,
and Chi3l1/YKL-40/BRP-39
(A) Triple-label IHC was used to detect the coloc-
alization of IL-13, IL-13Ra2, and Chi3l1/BRP-39
in lungs from IL-13 Tg mice using antibodies
to Chi3l1/BRP-39, IL-13Ra2, and IL-13. Arrows
highlight some of the colocalized cells.
(B) Lung lysates were prepared fromWT and IL-13
transgenic mice and immunoprecipitated (IP) with
anti-Chi3l1, anti-iL-13Ra2, or anti-iL-13, and the
precipitates were evaluated using immunoblot (IB)
analysis as noted.
(C) THP-1 cells were incubated with recombinant
(r) IL-13 or Chi3l1/YKL-40 (rChi3l1) alone and in
combination as noted. Western blot evaluations
were used to evaluate ERK1/2 phosphorylation,
total ERK1/2, AKT phosphorylation, and total AKT.
(D) Peritoneal macrophages from Chi3l1/ mice
were incubated overnight with rIL-13 (10 ng/ml),
cell lysates were prepared, rChi3l1 was added at
the noted doses, and immunoprecipitation and
immunoblot analysis was undertaken with anti-iL-
13 or anti-iL-13Ra2 antibodies as noted.
(E) THP-1 cells were incubated with rIL-13 and
rChi3l1 as indicated and western blot evaluations
were used to evaluate STAT6 phosphorylation
(STAT6-P) and total STAT 6 (STAT6-T).
(F) Peritoneal macrophages were isolated from
IL-13Ra2/ mice and transfected with empty
vector, full-length IL-13Ra2 (IL-13Ra2-myc), or
deletion mutants lacking IL-13 binding site 2
(IL-13Ra2dS2-myc) or site 3 (IL-13Ra2dS3-myc).
Cell lysates were prepared, incubated with rChi3l1
(500 ng) and rIL-13 (10 ng) overnight, and evalu-
ated using IP and IB with anti-myc, anti-iL-13, or
anti-Chi3l1 as noted.that Chi3l1, IL-13Ra2, and IL-13 colocalize in tissue sections
(Figure 3A) and participate in a multimeric complex, because
the immunoprecipitation of any one of the three always immu-
noprecipitated the other two (Figure 3B). In keeping with this
finding, studies that demonstrated that IL-13 can activate
MAPK (Cho et al., 2006; Lee et al., 2006) and studies that
demonstrated that IL-13 stimulates heparin binding-epidermal
growth factor (HB-EGF) via an IL-13Ra2-dependent mechanism
(Allahverdian et al., 2008) demonstrated that IL-13 also activates
macrophage MAPK and AKT via IL-13Ra2- and Chi3l1-depen-
dent pathways (Figure S3A and S3B). IL-13 did not compete
with Chi3l1/YKL-40/BRP-39 for IL-13Ra2 binding or signaling
(Figure 3C). Similarly, Chi3l1/YKL-40/BRP-39 did not compete
with IL-13 for IL-13Ra2 binding or signaling (Figure 3D). IL-13
was also a powerful activator of STAT6, Chi3l1/YKL-40 did not
activate STAT6, Chi3l1 did not inhibit IL-13-induced phosphory-
lation of STAT6, and IL-13 did not inhibit Chi3l1/YKL-40 activa-
tion of MAPK, AKT, or Wnt/b-catenin signaling (Figure 3E).
Structure-function evaluations also demonstrated that deletion
of amino acids corresponding to site II (IL-13Ra2dS2) and site
III (IL-13Ra2dS3) of IL-13Ra2, the reported IL-13 binding sites
in IL-13Ra2 (Lupardus et al., 2010), abrogates IL-13 binding
without abrogating Ch13l1 binding (Figure 3F). These studies
demonstrate that IL-13, Chi3l1/YKL-40, and IL-13Ra2 partici-
pate in a multimeric complex. They also demonstrate that834 Cell Reports 4, 830–841, August 29, 2013 ª2013 The AuthorsChi3l1/YKL-40 and IL-13 do not compete with one another for
IL-13Ra2 binding, do not abrogate each other’s signaling, and
do not bind to identical locations on IL-13Ra2.
Role of IL-13Ra2 in Oxidant-Induced Cell Death
Responses
Previous studies from our laboratory demonstrated that Chi3l1/
YKL-40/BRP-39 inhibits oxidant-induced lung injury and epithe-
lial cell apoptosis (Sohn et al., 2010). To determine if IL-13Ra2
plays a role in these responses, we compared the epithelial
cell death and pulmonary injury responses in WT, IL-13Ra2
null, YKL-40 Tg, and YKL-40 Tg/IL-13Ra2/ mice exposed to
room air or 100% O2 for 48 hr. Hyperoxia induced epithelial
apoptosis/DNA injury, alveolar-capillary protein leak, and
caspase-3 and caspase-8 activation in lungs fromWTmice (Fig-
ures 4A, 4B, and S4A; data not shown). Hyperoxia-induced
epithelial TUNEL responses and alveolar protein leak were
exaggerated in lungs from Chi3l1/BRP-39 null mice and a
phenocopy was seen in IL-13Ra2/ animals (Figures 4A and
4B). Transgenic YKL-40 ameliorated the hyperoxia-induced
responses in WT mice and rescued the exaggerated responses
in Chi3l1 null animals (Figures 4A and 4B). Importantly, the pro-
tective effects of YKL-40 were significantly decreased in Tg
mice that lacked IL-13Ra2 (Figures 4A and 4B). In accord
with these in vivo findings, epithelial cells treated with H2O2
Figure 4. Chi3l1 and IL-13Ra2 Regulation of
Cell Death and Acute Oxidant Injury
WT (+/+), Chi3l1/BRP-39 null (/), IL-13Ra2
null (/), Chi3l1/YKL-40 Tg (+), Chi3l1/YKL-40
Tg(+)/BRP-39(/), and Chi3l1/YKL-40 Tg(+)/IL-
13Ra2(/) mice were exposed to 100% O2 or
room air (100% O2 ) for 48 hr.
(A) TUNEL staining of lung sections from those
mice.
(B) BAL fluid total protein.
(C) Airway epithelial cells (1HAEo) were exposed
for 6 hr to H2O2 (800 mM). Cells were used that
had been treated with IL-13Ra2-specific siRNA
or scrambled controls and incubated in the
presence and absence of recombinant(r) Chi3l1.
Annexin V and propidium iodide staining was
evaluated by FACS analysis.
(D and E) Peritoneal macrophages from WT (+/+),
Chi3l1 null (/), and IL-13Ra2 null (/) mice
were incubated with H2O2 (H2O2 +) or its vehicle
control (H2O2 ) in the presence and absence of
rChi3l1/BRP-39, and TUNEL staining (D) and LDH
release (E) were evaluated.
Values in (A), (B), (D), and (E) represent the
means ± SEM of evaluations of a minimum of four
mice. (C) is representative of at least three similar
evaluations. *p < 0.05, **p < 0.01. NS, not signifi-
cant. See also Figure S4.in vitro manifest increased levels of apoptosis and necrosis and
these responses were exaggerated in cells that lacked Chi3l1/
YKL-40 or IL-13Ra2 (Figures 4C and S4B). The addition of
rChi3l1/YKL-40 to these cultures markedly decreased the cell
death responses in WT cells and rescued the exaggerated re-
sponses in Chi3l1/BRP-39 null mice but did not cause compara-
ble cytoprotection in cells that lacked IL-13Ra2 (Figures 4C and
S4B). These responses were not H2O2 or lung epithelial cell spe-
cific because similar responses were seen with FasL-treated
lung epithelial cells and H2O2-treated kidney epithelial cells (Fig-
ures S4C and S4D). They were also at least partially mediated by
the ability of Chi3l1/YKL-40/BRP-39 to activate AKT, because
selective AKT inhibitors abrogated the antiapoptotic effects of
Chi3l1/YKL-40/BRP-39 (Figure S4E; data not shown). Similarly,
exposure of murine peritoneal macrophages from WT mice to
H2O2 induced TUNEL staining and lactate dehydrogenase
(LDH) release, and these responses were further exaggeratedCell Reports 4, 830–841in cells from Chi3l1/BRP-39 null animals
(Figures 4D and 4E). A phenocopy was
seen in cells from IL-13Ra2 null mice,
which also manifest exaggerated levels
of TUNEL staining and LDH release after
H2O2 treatment (Figures 4D and 4E).
Once again, the TUNEL staining and
LDH release from macrophages from
WT and Chi3l1/BRP-39 null mice were
significantly ameliorated by treatment
with rChi3l1/BRP-39. In contrast,
rChi3l1/YKL-40 did not cause a similar
degree of cytoprotection in cells that
lacked IL-13Ra2 (Figures 4D and 4E).When viewed in combination, these studies demonstrate that
oxidant-induced injury and cell death responses are similarly in-
creased in vivo and in vitro in lungs, epithelial cells, and macro-
phages from Chi3l1/BRP-39 null and IL-13Ra2 null mice. They
also demonstrate that transgenic and recombinant Chi3l1/
YKL-40 rescue these exaggerated responses via IL-13Ra2-
dependent mechanisms.
Role of IL-13Ra2 in Pyroptosis
Because previous studies from our laboratory demonstrated that
Chi3l1/YKL-40/BRP-39 controls Streptococcus pneumoniae
(SP)-induced macrophage pyroptosis, SP-induced cell survival,
LDH release, and caspase-1 activation were evaluated in cells
from WT, Chi3l1/BRP-39 null, and IL-13Ra2 null mice. Incuba-
tion with SP increased TUNEL staining and LDH release from
cells from WT mice, and this response was further exaggerated
in cells from Chi3l1/BRP-39 null animals (Figures 5A and 5B)., August 29, 2013 ª2013 The Authors 835
Figure 5. Chi3l1 and IL-13Ra2 Regulation of
SP-Induced Responses
(A and B) Peritoneal macrophages from WT (+/+),
Chi3l1 null (/), and IL-13Ra2 null (/) mice
were incubated with SP (SP+) or its vehicle control
(SP) in the presence and absence of rChi3l1/
BRP-39, and TUNEL staining (A) and LDH release
(B) were assessed.
(C) Western blotting was also used to evaluate cell
lysate caspase-1 activation.
(D) Peritoneal macrophages from WT (+/+), Chi3l1
null (/), and IL-13Ra2 null (/) mice were also
incubated with SP (SP+) or SP preincubated for
60 min without antibiotics with rChi3l1/BRP-39
at a 10:1 SP-to-cell ratio (SP/rChi3l1). They were
then incubated with gentamicin to kill extracellular
bacteria and the viable bacteria in the cell lysates
were assessed 6 hr later.
Values in (A), (B), and (D) are the means ± SEM of
triplicate measurements and are representative
of a minimum of three similar evaluations; (C) is
representative of three similar evaluations. *p <
0.05, **p < 0.01. NS, not significant.These responses in cells fromWTmice were not associated with
significant increases in caspase-1 activity (Figure 5C). However,
increased caspase-1 was seen in SP-infected cells from Chi3l1/
BRP-39 null mice (Figure 5C). A phenocopy was seen in cells
from IL-13Ra2 null mice, which also manifest exaggerated levels
of TUNEL staining, LDH release, and caspase-1 activation after
SP infection (Figures 5A–5C). Importantly, the exaggerated TU-
NEL staining, LDH release, and caspase-1 activation in Chi3l1/
BRP-39 null mice were significantly rescued by treatment with
rChi3l1/BRP-39. In contrast, rBRP-39/YKL-40 did not compa-
rably rescue the exaggerated cell death phenotype and cas-
pase-1 activation in IL-13Ra2 null cells (Figures 5A–5C). In
accord with these studies, the defects in bacterial killing that
were seen in macrophages from Chi3l1/BRP-39 null mice (Dela
Cruz et al., 2012) were phenocopied in macrophages from IL-
13Ra2 null mice (Figure 5D), and the former was rescued with
rChi3l1 while the latter was not significantly altered by this re-
combinant protein (Figure 5D). When viewed in combination,
these studies demonstrate that SP-induced pyroptosis is
increased in a similar manner in macrophages from Chi3l1/
BRP-39 null and IL-13Ra2 null mice and that rChi3l1/BRP-39
rescues this exaggerated phenotype via an IL-13Ra2-dependent
mechanism.
Role of IL-13Ra2 in Inflammasome Activation
Studies were also undertaken to define the role(s) of IL-13Ra2 in
the regulation of inflammasome activation by Chi3l1/YKL-40/
BRP-39. In these experiments, incubation of macrophages
from WT mice with SP stimulated the production of IL-1b and
the accumulation of IL-1b mRNA (Figure S5A). Under these cir-
cumstances, a significant increase in pro-IL-1b and a more
modest increase in the levels of mature IL-1b could also be836 Cell Reports 4, 830–841, August 29, 2013 ª2013 The Authorsappreciated in cells and supernatants
from these cultures (Figures 6A–6D).
Both of these responses wereexaggerated in cells from Chi3l1/BRP-39 null mice (Figures
6A–6D). Enhanced levels of pro-IL-1b were also seen in cells
from SP-treated IL-13Ra2 null mice (Figures 6A–6D). In keeping
with the increased levels of caspase-1 activity in these cells,
increased levels of cell-associated and supernatant mature IL-
1b were also seen in cultures of SP-treated IL-13Ra2 null cells
(Figures 6B and 6D). Importantly the exaggerated mature IL-1b
responses in Chi3l1/BRP-39 null mice were ameliorated by
treatment with rChi3l1/BRP-39. In contrast, rChi3l1/BRP-39
did not rescue the exaggerated inflammasome activation in IL-
13Ra2 null cells (Figures 6C and 6D). These studies demonstrate
that Chi3l1/YKL-40/BRP-39 inhibits SP-induced inflammasome
activation via an IL-13Ra2-dependent mechanism.
Role of IL-13Ra2 in SP infection In Vivo
Previous studies from our laboratory demonstrated that Chi3l1/
BRP-39 plays a critical role in antipneumococcal responses
where it augments bacterial killing by inhibiting macrophage
pyroptosis and inhibits inflammasome activation (Dela Cruz
et al., 2012). In keeping with the in vitro observations noted
above, studies were undertaken to define the roles of IL-
13Ra2 in in vivo anti-SP responses. SP infection caused a brisk
neutrophil-rich inflammatory response that was associated with
significant induction of BAL IL-1b (Figures S5B and S5C). These
responses and pyroptosis-associated caspase-1 activation
were exaggerated and bacterial clearance was decreased in
Chi3l1/BRP-39 null mice (Figures 6E and 6F). The SP-induced
responses in IL-13Ra2 null mice were very similar to those in
the Chi3l1/BRP-39 null mice with enhanced BAL and tissue
inflammation, IL-1b production, caspase-1 activity, and bacte-
rial accumulation (Figures S5B, S5C, 6E, and 6F). Importantly,
rChi3l1/YKL-40 successfully ameliorated the exaggerated
Figure 6. Chi3l1 and IL-13Ra2 Regulation of
SP-Induced Inflammasome Activation
Peritoneal macrophages were obtained from
WT mice, Chi3l1/BRP-39 null (/) mice, and IL-
13Ra2 null (/) mice and incubated with SP.
(A) The kinetics of IL-1b production were evaluated
by ELISA.
(B) IL-1b maturation and release into the cell su-
pernatant (SN) was evaluated by western blotting.
(C–F) The ability of rmChi3l1/BRP-39 to modulate
IL-1b production (C) and maturation (D) caspase-1
activity measured by ELISA (E) and bacterial load
were also evaluated.
Values in (A), (C), (E), and (F) are the means ± SEM
of triplicate measurements and are representative
of a minimum of three similar evaluations. (B) and
(D) are representative of three evaluations. *p <
0.05. NS, not significant.responses in Chi3l1/BRP-39 null mice but did not have similar
corrective effects in mice that lacked IL-13Ra2 (Figures S5B,
S5C, 6E, and 6F). These studies demonstrate that IL-13Ra2
plays an important role in Chi3l1/YKL-40/BRP-39 regulation of
pulmonary antibacterial responses in vivo.
Role of IL-13Ra2 in Chi3l1/YKL-40 Stimulation of
Melanoma Metastasis and TGF-b1 Production In Vivo
Recent studies have demonstrated that pulmonary melanoma
metastasis is mediated via an IL-13Ra2-dependent mechanism
that requires the production of TGF-b1 (Fichtner-Feigl et al.,
2008b; Strober et al., 2009). As a consequence, studies were
undertaken to determine if Chi3l1/YKL-40/BRP-39 plays a role
in this response and if it does so via IL-13Ra2. To accomplish
this, we compared the B16-F10 melanoma cell-induced metas-
tasis and TGF-b1 elaboration in WT mice, YKL-40 Tg mice,
and IL-13Ra2 null mice. Melanoma cell administration caused
impressive levels of metastasis in lungs from WT mice, and
this metastatic response was markedly increased in Tg mice in
which YKL-40 was selectively targeted to the lung (Figures 7ACell Reports 4, 830–841and 7B). In accord with the studies of
Strober et al. (Fichtner-Feigl et al.,
2008b; Strober et al., 2009), these meta-
static responses were associated with
modest increases in the levels of TGF-
b1 in WTmice and significantly enhanced
levels of total and activated TGF-b1 in
melanoma-challenged YKL-40 Tg ani-
mals (Figures 7C and 7D). Importantly,
the metastatic responses in the WT and
Tg mice and the levels of TGF-b1
production were both significantly
decreased in mice with null mutations of
IL-13Ra2 (Figures 7A–7D). When viewed
in combination, these studies demon-
strate that endogenous Chi3l1/BRP-39
and transgenic Chi3l1/YKL-40 regulate
pulmonary melanoma metastasis and
the TGF-b1 elaboration that underliesthese responses. They also demonstrate that the effects of
Chi3l1/YKL-40/BRP-39 in this setting are mediated, at least in
part, by IL-13Ra2.
DISCUSSION
IL-13Ra2 was described as a high-affinity receptor for IL-13 that
is distinct from the IL-13Ra1-IL-4Ra receptor dimer that IL-13
shares with IL-4 (Lupardus et al., 2010; Strober et al., 2009).
It was initially believed to be a decoy receptor because it only
contains a 17-amino-acid cytoplasmic domain that lacks a
conserved box 1 region that plays a critical role in signal trans-
duction (Konstantinidis et al., 2008) and early studies highlighted
its ability to diminish IL-13 responses (Chiaramonte et al., 2003;
Lupardus et al., 2010; Wood et al., 2003). However, more recent
studies have demonstrated that IL-13 also signals and regulates
a variety of cellular and tissue responses via IL-13Ra2 (Daines
et al., 2006; Fichtner-Feigl et al., 2006, 2007, 2008a, 2008b;
Strober et al., 2009; Yang et al., 2010, 2011). The explanation
for these different points of view has not been defined. The, August 29, 2013 ª2013 The Authors 837
Figure 7. Chi3l1 and IL-13Ra2 in Melanoma
Metastasis and TGF-b1 Production In Vivo
WTmice, IL-13Ra2 null (/) mice, Chi3l1/YKL-40
Tg mice (Tg+), and Chi3l1/YKL-40 Tg/IL-13Ra2
null mice received B16-F10 melanoma cells by
tail-vein injection.
(A) Fourteen days later, melanomametastasis was
visually assessed.
(B) Quantification of pleural melanoma colonies.
(C) ELISA evaluation of total BAL TGF-b1.
(D) ELISA evaluation of activated TGF-b1. (A) is
representative of three similar evaluations.
Values in (B)–(D) are the means ± SEM of triplicate
measurements and are representative of a mini-
mum of three similar evaluations. *p < 0.05.present studies, however, provide insights into mechanisms that
may contribute to these disparate findings because they demon-
strate that IL-13 is not the only ligand for IL-13Ra2. Specifically,
they characterize the first receptor for any GH 18 moiety by
demonstrating that the chitinase-like protein (CLP) Chi3l1 binds
to, signals, and regulates oxidant injury, apoptosis, pyroptosis,
inflammasome activation, pathogen responses, melanoma
metastasis, and TGF-b1 via IL-13Ra2.
Endogenous lectins such as C-type lectins, siglecs, and galec-
tins bind N- and O-linked glycans, resulting in regulatory signals
that control immune cell homeostasis and integrate circuits that
amplify or silence immune responses (Rabinovich and Croci,
2012). These lectins recognize complex glycan determinants
with relatively high affinity, often in the micromolar range
(Rabinovich and Croci, 2012; Sulak et al., 2009). CLPs are also
lectins and are frequently referred to as chi-lectins. In keeping
with other lectin-glycan interactions, our studies demonstrate
that Chi3l1 binds to the glycopeptide IL-13Ra2 (Kioi et al., 2006)
with high affinity. They also demonstrate that this interaction is
dependent on the CD and chitin binding motif of Chi3l1 and the
extracellular domain of IL-13Ra2 but did not require IL-13Ra2
N-glycosylation. When combined with our demonstration that
Chi3l1 signals and regulates cellular and tissue responses, these
findings allow for theexcitinghypothesis that IL-13Ra2 is a recep-
tor for Chi3l1, putting the Chi3l1-IL-13Ra2 complex at the inter-
face of glycobiology and protein biology (Coffman, 2008). It is
important to point out, however, that our studies do not demon-
strate that IL-13Ra2 is the only receptor for Chi3l1/YKL-40//
BRP-39. In fact, our studies suggest that other receptors may
exist because, in some of our experimental systems, the elimina-838 Cell Reports 4, 830–841, August 29, 2013 ª2013 The Authorstion of IL-13Ra2 only partially abrogated
the specific Chi3l1/YKL-40/BRP-39
effector response.
Studies were also undertaken to define
the interactions of IL-13, IL-13Ra2, and
Chi3l1/YKL-40/BRP-39. These studies
demonstrate that these moieties exist in
tissuesandfluids in amultimeric complex.
Our studies do not address the details
of the Chi3l1-IL-13Ra2-IL-13 complex.
However, modeling of other lectin-glycan
interactions has revealed two- and three-dimensional arrangements of multivalent lectins and glycans in
‘‘lattices’’ that serveas scaffolds that organizeplasmamembrane
domains and modulate the signaling thresholds of relevant sur-
face glycoproteins and receptors (Rabinovich and Croci, 2012).
Thus, it is possible that Chi3l1, IL-13Ra2, and IL-13 are part of a
largemultimeric complexor ‘‘chitosome’’ that could includeother
glycoproteinsand lectins.Additional investigationwill be required
to evaluate the nature of the IL-13Ra2-Chi3l1 complex and its
relationship to IL-13 and other Chi3l1 receptors.
Using concentrations of Chi3l1 that can be seen in the circula-
tion of healthy individuals and in patients with disease, these
studies demonstrated that Chi3l1 can activate MAPK and AKT
cellular signaling pathways (Areshkov et al., 2012; Chen et al.,
2011a; Eurich et al., 2009; Kim et al., 2012; Shao et al., 2009).
Our studies added to these observations by demonstrating
that Chi3l1 activates theWnt/b-catenin signaling and by demon-
strating that IL-13Ra2 is required for the optimal activation of
each of these signaling pathways. These findings are in keeping
with the reported ability of IL-13 to activate MAPKs, Wnt/b-cate-
nin, and AKT (Moriya et al., 2011; Ooi et al., 2012; Wang et al.,
2008) and the ability of IL-13 to stimulate epithelial HB-EGF via
IL-13Ra2 (Allahverdian et al., 2008). Lastly, our studies demon-
strate that the antiapoptotic effects of Chi3l1/YKL-40/BRP-39
are mediated, at least in part, by its ability to activate AKT.
When viewed in combination, it is tempting to speculate that
these signaling events, in addition to their contribution to the anti-
apoptotic effects of Chi3l1, also contribute to its inflammatory,
angiogenic, neoplastic, and other effector responses (Chen et al.,
2011b; Coffman, 2008; Eurich et al., 2009; Faibish et al., 2011;
Kawada et al., 2012; Lee et al., 2009; Shao et al., 2009).
To define the role(s) of the intracellular domain of IL-13Ra2 in
the signaling events that were noted, we compared the effects
of Chi3l1 in cells from IL-13Ra2/ mice that were transfected
with constructs that encoded full-length IL-13Ra2, constructs
that lacked the intracellular domain of IL-13Ra2, and controls.
These studies demonstrated that the MAPK and AKT activation
events did not require the intracellular domain of the receptor.
In contrast, the intracellular domain played a critical role in the
activation of theWnt/b-catenin/AP-1 pathway. The latter findings
are in full accordwith reports by Fichtner and Feigl (Fichtner-Feigl
et al., 2006).Whenviewed in combination, these findingshighlight
the different roles of the intracellular domain of IL-13Ra2 in
Chi3l1-induced cell signaling. They also raise the interesting
question, howdoesChi3l1 activateERKandAKTwithout an intra-
cellular domain? Preliminary studies in our laboratory support the
possibility that a coreceptor may be involved. However, addi-
tional investigationwill be required to fully address this possibility.
Chi3l1/YKL-40/BRP-39mayplay a particularly important role in
cancer (Coffman, 2008; Goel et al., 2007; Lee et al., 2011). Recent
studiesby theStrobergroupalsohighlighted the importanceof IL-
13Ra2 in the progression of malignant melanoma, where its acti-
vation by IL-13 causedTGF-b1 elaboration,which inhibited tumor
immune surveillance and favored tumor growth (Fichtner-Feigl
et al., 2008b; Strober et al., 2009). Previous studies from our lab-
oratory demonstrated that IL-13 stimulates TGF-b1 via a Chi3l1/
BRP-39-dependent mechanism (Lee et al., 2009). The present
studies add to these observations by demonstrating that Tg
Chi3l1/YKL-40 stimulates TGF-b1 in lungs with metastatic mela-
noma via an IL-13Ra2-dependent mechanism. Interestingly,
they also demonstrated that IL-13Ra2 plays a particularly impor-
tant role in theproductionofbioactiveTGF-b1 in this setting. Thus,
in accord with the findings by Strober et al. and prior studies that
demonstrate that the levels of circulating Chi3l1/YKL-40 are
increased in patients with advanced melanoma (Schmidt et al.,
2006), an IL-13-Chi3l1/YKL-40-IL-13Ra2-TGF-b1 axis appears
to play a critical role in the progression of malignant melanoma.
These studies also suggest that IL-13Ra2-dependent mecha-
nisms may play an important role in TGF-b1 activation.
In keeping with the retention of CLP over species and evolu-
tionary time, recent studies have demonstrated that Chi3L1 plays
essential roles in pathogen clearance and the generation of host
tolerance (Dela Cruz et al., 2012). In the setting of pneumococcal
lung infection, Chi3l1 augments bacterial killing and clearance by
controlling pyroptosis (Dela Cruz et al., 2012). This prevents the
bacteria from killing the macrophage before the macrophage
can kill the bacteria (Dela Cruz et al., 2012). Simultaneously,
Chi3l1 diminishes innocent-bystander tissue injury by controlling
innate immune inflammasome and purinergic pathway activation
(Dela Cruz et al., 2012) and decreases tissue oxidant injury (Sohn
et al., 2010). To define the roles of IL-13Ra2 in these events, we
characterized these responses in WT mice and Chi3l1/BRP-39
null mice and evaluated the ability of Tg Chi3l1/YKL-40 to rescue
these responses in mice with WT and null IL-13Ra2 loci. These
studies demonstrate that, in the absence of Chi3l1/BRP-39,
pneumococcus causes exaggerated macrophage cell death,
inflammation, and tissue injury and decreased bacterial clear-
ance and that each of these responses was significantly amelio-
rated by Tg Chi3l1/YKL-40. They also demonstrate that, in theabsence of Chi3l1/BRP-39, oxidants caused exaggerated
cellular apoptosis, which was rescued by Chi3l1/YKL-40. Impor-
tantly, qualitatively similar responses were seen in IL-13Ra2 null
animals and cells exposed to pneumococcus or H2O2. However,
the ability of Chi3l1/YKL-40/BRP-39 to rescue the phenotypes in
IL-13Ra2 null mice and or cells was decreased compared to the
effects of Chi3l1/YKL-40 in mice and cells that lacked Chi3l1/
BRP-39. This demonstrates that Chi3l1 controls pyroptosis,
apoptosis, inflammasome activation, and antipneumococcal
responses by binding to and activating IL-13Ra2. This further
reinforces the concept that IL-13Ra2 is a receptor for Chi3l1
and more than just a ‘‘decoy’’ receptor for IL-13.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice (the Jackson Laboratory) were bred at Yale. Chi3l1/BRP-39
null mutant mice (Chi3l1/) and YKL-40 and IL-13 Tg mice were generated
and characterized in our laboratory as previously described (Lee et al., 2009;
Zhu et al., 1999). IL-13Ra2 null mice (IL-13Ra2/) were purchased from
The Jackson Laboratory and backcrossed to C57BL/6 backgrounds. All
murine procedures were approved by the Institutional Animal Care and Use
Committee at Yale University.
Yeast Two-Hybrid Screening
The full-length murine Chi3l1 gene was amplified by PCR from mouse lung
complementary DNA (cDNA) using the following primers: forward, 50-CCCC
GGGCTGCAGGGATCCGG CAGAGAGAAGCCATC-30; reverse, 50-CATATG
GGAAAGGTCGACCTAAGCCAG GGCATCCTT-30). The Chi3l1 DNA was
cloned into the yeast two-hybrid BD vector at the BamHI and Sal1 sites. The
Matchmaker System 3 two-hybrid assay using S. cerevisiae (Clontech)
was used to detect interactions between Chi3l1 and other cellular proteins.
S. cerevisiae strain AH109 (Clontech) containing the four reporter genes
ADE2, HIS3, MEL1, and lacZ was cotransfected with the pGBKT7-Chi3l1
bait plasmid and the mouse lung cDNA library (Clontech) constructed into
the vector pAC2 by the lithium acetate method. Additional experimental
details are included in the Extended Experimental Procedures.
Coimmunoprecipitation
Proteins from the lysate, culture supernatant, or BAL fluid were clarified
by centrifugation for 10 min at 4C. Chi3l1/YKL-40 and human IL-13Ra2
were immunoprecipitated with anti-YKL-40 rabbit polyclonal antibody
(MedImmune) or anti-hIL-13Ra2 monoclonal antibody (RayBiotech), respec-
tively, using Catch and Release V2.0 (Reversible Immunoprecipitation System,
EMD Millipore). The precipitates were subjected to immunoblotting with
antibodies against IL-13Ra2 or YKL-40, respectively.
Double-Label Immunohistochemistry
To localize the expression of BRP-39 and IL-13Ra2, double-label IHC was
undertaken with a modification of procedures described previously by our
laboratory (Lee et al., 2009). Additional experimental details are included in
the Extended Experimental Procedures.
Expression and Purification of IL-13, IL-13Ra2, and YKL40
Genes encoding residues 21–132 of human IL-13, ectodomain residues 29–
331 of human IL-13Ra2 (IL-13Ra2-ECD), or human YKL40 were subcloned
into the pAcGP67 vector (BD Biosciences) in frame with the baculovirus
gp67 signal sequence and followed by the sequence PHHHHHH. Sf9 insect
cells (Invitrogen) were cotransfected with one of the above expression
constructs and DiamondBac baculovirus genomic DNA (Sigma-Aldrich) to
produce recombinant baculoviruses expressing IL-13 or IL-13Ra2-ECD, or
YKL40. Virus stocks were amplified with three sequential infections of Sf9
cells. The three proteins were expressed and purified following the same
protocol. Tni insect cells (Expression Systems) grown at 27C were infected
at a density of 2 3 106 cells/ml with 1.0% (v/v) of third-passage (P3)Cell Reports 4, 830–841, August 29, 2013 ª2013 The Authors 839
recombinant baculovirus stock. After culture in suspension for 96–105 hr at
20C, the culture media was collected and its pH was adjusted with 10 mM
HEPES pH 7.5. The overexpressed protein was purified by nickel-affinity
chromatography with a HisTrap HP column (GE Healthcare), followed by
size-exclusion chromatography on a Superdex 200 10/300 GL column (GE
Healthcare). The size-exclusion buffer was 10 mM HEPES pH 7.5, 50 mM
NaCl, and 0.5 mM CaCl2. Protein concentrations were measured by UV spec-
troscopy at 280 nm using a Nanodrop2000 spectrometer (Thermo Scientific).
Kinetic Binding Analysis by Surface Plasmon Resonance
Surface plasmon resonance experiments were performed with a CM5 sensor
chip, at 25C on a Biacore T100 instrument (GE Healthcare). YKL40 was
captured at a low density (2,000–4,000 response units) by direct amine-based
coupling. The ethanolamine-blocked surface acted as a reference for the
CM5 sensor chip. Dose-response experiments were performed as 3-fold
serial dilutions of IL-13Ra2-ECD in running buffer (10 mM HEPES pH 7.4,
150 mM NaCl). The sensor chip was regenerated with 10 mM NaOAc pH 4.0
and 250 mM NaCl. IL-13Ra2/YKL40 binding kinetics were measured during
180 s association and 780 s dissociation phases, with a flow rate of 45 ml/min.
Data were analyzed with the Biacore T100 evaluation software version 2.0
with a 1:1 Langmuir bindingmodel. All experimentswere performed in triplicate.
Deletion Mapping
Deletion mutants of Chi3l1/YKL-40 and IL-13Ra2 were generated using PCR
amplification using primers listed in Tables S1 and S2. The yeast two-hybrid
assay was used to evaluate the interactions of each deletion mutants of
Chi3l1 and IL-13Ra2 with full-length IL-13Ra2 and Chi3l1, respectively.
Nuclear Protein Extraction
The nuclear and cytoplasmic protein fraction from cultured peritoneal macro-
phage was extracted using NE-PER Nuclear and Cytoplasmic Extraction kit
(Thermo Scientific) as per the manufacturer’s instructions.
Immunoblotting
Protein lysates were prepared from cultured cells or whole lungs using RIPA
lysis buffers and subjected to immunoblotting using a modification of proce-
dures described previously by our laboratory (Lee et al., 2009). Additional
experimental details are included in the Extended Experimental Procedures.
RNA Interference Analysis
Human IL-13Ra2 siRNAs (Santa Cruz Biotechnology) were used to knock
down IL-13Ra2 according to the protocols provided by the manufacturer.
Cells were plated on six-well plates and transfected the next day with
IL-13Ra2 or control siRNAs. The cells were harvested at the indicated time
points and were subjected to real-time RT-PCR or western blot evaluations.
Cell Death Evaluations
Cell death and DNA injury were evaluated with TUNEL and FACS analyses of
Annexin V and propidium iodide (PI) staining as previously described by our
laboratory (Lee et al., 2009). The in vivo cell death response was evaluated
after the mice (WT, Chi3l1/, and IL-13Ra2/ mice) were exposed to 100%
oxygen or room air for up to 3 days as described previously (Sohn et al.,
2010). The in vitro evaluations were done under control conditions,
after incubation with H2O2 (J. T. Baker Chemical; 500–800 mg/ml) or after incu-
bation with rFasL (Peprotech). 1HAEo-transformed lung airway epithelial cells
were obtained from Dr. D. Greunert (University of California, San Francisco).
Peritoneal macrophages and proximal renal tubular epithelial cells were iso-
lated from WT, Chi3l1/, and/or IL-13Ra2/ mice in these in vitro cell death
evaluations. AKT inhibitor (Akt-In) was purchased from EMD Millipore.
Lactate Dehydrogenase Test
Supernatant LDH was measured using the Cytotoxicity Detection Kit (LDH;
Roche Applied Science) as per the manufacturer’s instructions.
Bacterial Infection
In vivo and in vitro bacterial infection was done as previously described in our
laboratory (Dela Cruz et al., 2012).840 Cell Reports 4, 830–841, August 29, 2013 ª2013 The AuthorsQuantification of Caspase-1 Bioactivity
Caspase-1 bioactivity was assessed using the Caspase 1 Colorimetric Assay
Kit (Millipore) as per the manufacturer’s instructions.
Assessment of Melanoma Lung Metastasis
Mouse melanocytes (B16-F10), established from C57BL6/J mouse skin
melanoma, were purchased from the American Type Culture Collection
(CRL-6475). After culture to confluence in ordinary Dulbecco’s modified
Eagle’s medium (DMEM), the cells were delivered to themice by tail-vein injec-
tion (2 3 105 cells/mouse in 200 ml of DMEM). Lung melanoma metastases
were quantified by counting the number of colonies (which appear as black
dots) on the pleural surface.
Quantification of TGF-b1 and IL-1b
The levels of BAL fluid Th2 cytokines and active and total TGF-b1 (before and
after acid activation, respectively) were measured by ELISA using commercial
kits (R&D Systems) as directed by the manufacturer.
Statistical Analysis
Normally distributed data are expressed as mean ± SEM and were assessed
for significance by Student’s t test or ANOVA as appropriate. Statistical sig-
nificance was defined at a p value less than 0.05. All statistical analyses
were performed with SPSS version 13.0 (SPSS). Statistical significance was
defined at a level of p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Extended Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
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